Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate. The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:… Read More
Palomar Labs (formerly Negev Labs), a venture studio that builds companies around neuropsychiatric drug development programmes with prior human validation, has announced the spinout of Ariadne Bio, its first portfolio company. Ariadne Bio launches with lead programme AB-300, a clinical-stage-ready, non-hallucinogenic serotonin 2A receptor agonist in development… Read More
A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding. Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how… Read More
AI start-up deepmirror has been awarded a Phase 2 Sovereign AI grant as part of Innovate UK’s support for British businesses building world-leading AI technologies. The grant will fund deepmirror’s data acquisition strategy in which it selects the experiments most likely to improve its molecular… Read More
Biotechnology company Immutrin has raised £65 ($86.7) million in Series A financing to help fund its lead asset through clinical proof of concept. Immutrin’s lead asset is targeting ATTR cardiomyopathy, a serious and potentially fatal form of amyloidosis. Amyloidosis is a group of rare,… Read More
Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange. Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary… Read More
Atrium Therapeutics has launched as a newly independent, publicly traded company developing RNA therapeutics for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences’ acquisition by Novartis. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO),… Read More
OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing. The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital. Founded in March 2025, Shanghai-based OTR Therapeutics… Read More
Two European biotech venture funds have raised over €1.1 billion in capital in the last week. Sofinnova Partners announced the close of Sofinnova Capital XI at €650 million, while Medicxi closed its Medicxi V fund at €500 million. Sofinnova Capital XI attracted strong support from… Read More
Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout. The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of… Read More
AI-driven biotechnology company Tres Alchemix has closed its $4.4 million Series A financing round, the company has announced. New funding will be used to accelerate the development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a… Read More
New research into the UK life sciences landscape has revealed a growing trend of investment into more mature companies. Pioneer Group’s ‘Life Science Start Up Report’ also highlights a persistent regional imbalance, with ‘Golden Triangle’ university spinouts attracting significantly more funding than… Read More
Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours. Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment. Dispatch’s Flare platform has… Read More
OutSee has secured £1.8 ($2.4) million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the company’s in-house… Read More
Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has collaborated with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational… Read More
Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting. This is RBL’s first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for… Read More
